PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...
Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This abstract does not include a ...
Shifting patterns of care in localized prostate cancer: Impact on patient reported outcome measures (PROMs). This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...
Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...
Many patients with PI-RADS 5 lesions on multiparametric MRI scans, which indicates a very high likelihood of clinically significant prostate cancer, have negative findings on standard template biopsy, ...
Adding baseline MRI to conventional prostate cancer risk stratification could improve prognostic accuracy, potentially affecting active surveillance and treatment decisions for some patients, ...
Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management TEL AVIV, Israel & SAN JOSE, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results